Ontario Denied Dying Cancer Patient Out-of-Country Treatment — Court Quashed the Decision
TL;DR
Ontario refused to pay for Alex Shved, a Toronto father with stage 4 melanoma, to get a Health Canada-approved cell therapy in the U.S. On Sept 22, 2026, a three-judge Divisional Court panel quashed that refusal as unreasonable and ordered a new decision by Oct 2, noting he "will likely be dead by Christmas" without treatment.
Who was hurt
- Alex Shved
Ontario denied Shved out-of-country funding for tumour-infiltrating lymphocyte (TIL) therapy, a Health Canada-approved treatment for his stage 4 melanoma. He sought judicial review and represented himself at the September 8, 2026 hearing. On September 22, 2026, the Divisional Court quashed the denial as unreasonable and ordered a new decision by October 2, finding the record showed he "will likely be dead by Christmas if he does not receive the requested treatment within a few weeks" (Star, Globe).
Key: People Related scandals
The web
2 peopleWhy it matters
Alex Shved is a 37-year-old Etobicoke father of two young daughters with metastatic (stage 4) melanoma. He wants tumour-infiltrating lymphocyte (TIL) therapy, sold as lifileucel (brand name Amtagvi). Health Canada approved it (in August 2025, according to the Globe and Mail), but provincial drug plans do not cover it yet. He applied to Ontario for out-of-country coverage and was refused. His appeal to the Health Services Appeal and Review Board was dismissed, the Toronto Star reported.
On Sept 22, 2026, a three-judge panel of the Divisional Court (Ontario Superior Court of Justice) set aside those decisions. It found the justifications unreasonable and inadequately explained. The court's reasons, quoted by both outlets, said: "The record discloses that he will likely be dead by Christmas if he does not receive the requested treatment within a few weeks." According to the Star, the panel also said the province "provided no evidence" that funding his treatment would undermine drug-price negotiations.
The province's position is on the record. The Globe reported that Ontario told Shved the out-of-country program "isn't intended to be used as an interim funding route" for drugs that could later get public coverage. Before the ruling, a spokesperson for Health Minister Sylvia Jones told the Star that provinces do not fund out-of-country treatment for drugs that have not finished Canada's drug-funding process. The Star notes that this process "can take more than two years." Jones's office did not comment on the ruling.
The outlets report the cost differently, and the two figures measure different things. The Star reports that a Florida hospital quoted $1.3 million in total. The Globe reports that one lifileucel treatment costs US$515,000, not counting the hospital stay.
Legal actions
Court: Divisional Court (Ontario Superior Court of Justice). Applicant: Alex Shved, who represented himself. Respondent: Ontario / Ontario Public Drug Programs. No case name or citation has been published.
Shved filed for judicial review in June 2026, after Ontario denied his application for out-of-country coverage of TIL therapy (lifileucel) and the Health Services Appeal and Review Board dismissed his appeal, the Toronto Star reported. The hearing was on Sept 8, 2026.
On Sept 22, 2026, the panel set aside the decisions as unreasonable and inadequately explained, and sent the matter back to the executive officer of the Ontario Public Drug Programs. A new decision is due by Oct 2, 2026 (Star). The applicant won at this stage. Justices Jean-Marc Labrosse and Sharon Shore formed the majority. Justice David Corbett agreed that the decisions should be quashed, but he would have directed the executive officer to recommend the treatment (Globe and Mail).
Government response, Oct. 6, 2026. On Oct. 6, 2026, the Ministry of Health said that, "with respect to the recent decision of the Ontario Divisional Court concerning out-of-country drug funding, the government is exploring all available options, including an appeal and/or seeking a mutually satisfactory resolution of the matter with the applicant to the court." The same day it announced it had amended Regulation 552 of the Health Insurance Act to restrict out-of-country drug funding to cases meeting specific conditions (Ontario Newsroom). The release does not name Alex Shved; that it refers to this case is an inference. Whether the Ontario Public Drug Programs issued the new decision the court ordered by Oct. 2, and whether the amendment applies to his request, have not been reported.
Applicant: Sabrina Apitz-Grossman. Respondent: Ontario (out-of-country prior approval program). Filed: Oct. 6, 2026. Court: not stated in the reporting. No file number has been published.
Ontario refused in April 2026 to fund Tecelra, a T-cell receptor therapy available in the U.S., for her stage-four synovial sarcoma, and the Health Services Appeal and Review Board dismissed her appeal. Her application asks the court to quash the decision, order the province to reconsider, and hear the case on an expedited basis (The Trillium, Oct. 20, 2026). She filed on the day the province amended Regulation 552 to narrow out-of-country drug funding. The Trillium is the only outlet to report the filing; The Canadian Press (Oct. 21) covers her denials but not the court case. No hearing date has been reported.
Rippling effects
The ruling sent the matter back, rather than directing an outcome, to the executive officer of the Ontario Public Drug Programs. A new decision is due by Oct 2, 2026, the Star reported. The court expedited the review.
The panel was not unanimous on what should happen next. According to the Globe, Justices Jean-Marc Labrosse and Sharon Shore formed the majority. Justice David Corbett agreed that the decisions should be quashed, but he would have directed the executive officer to recommend the treatment.
Shved says his case is not the only one. He told the Star that he knows of at least two Ontario patients with the same cancer who died after being denied out-of-country TIL access. He also told the Globe that he spoke directly with Minister Jones and that "she has done nothing." These are Shved's own claims. Jones's office did not comment on the ruling.
The case turns on a gap in timing. A treatment can be approved by Health Canada but not yet covered by provincial drug plans, and the province's position is that the out-of-country program should not fill that gap while the national funding process runs, a process the Star says "can take more than two years." In Shved's case, the court found the province's justifications for refusing him unreasonable and inadequately explained, and it gave Ontario until Oct 2 to decide again.
The October 2026 rule change. On Oct. 6, 2026 the province amended Regulation 552 of the Health Insurance Act to narrow out-of-country drug funding. The Trillium reported that the change is retroactive to Oct. 1, 2011 and could affect applications and appeals already under way, and that the province said it would limit a rise in requests "which would otherwise incur up to $170 million in additional annual costs." The government also said the change would avoid "up to $5.2 billion" in additional costs every year. The Canadian Press reported that the source of that figure was unclear in the release, and that a government official later explained it as the additional cost if the province entirely stopped negotiating drug prices with manufacturers for public coverage. A second patient, Sabrina Apitz-Grossman, filed for judicial review of her own denial the same day (The Trillium).
Sources
- Ontario must reconsider denying cancer patient access to new treatment in U.S., court rules — Toronto Star
- Ontario court sides with patient appealing province's refusal to cover out-of-country cancer treatment — The Globe and Mail
- Ontario court orders 3rd OHIP review of out-of-country treatment for man with terminal cancer — CBC News
- Ontario Clarifies Longstanding Out-of-Country Drug Funding Process — Ontario Newsroom
- Toronto cancer patient feels 'betrayed' as Ontario tightens rules on out-of-country funding — Toronto Star
- 'People are just being told to die': Cancer patient takes Ford government to court for refusing to fund potentially life-saving U.S. treatment — The Trillium
- Ontario drug funding decision leaves cancer patients disappointed, with few options — CTV News (The Canadian Press)
- 'These are very challenging decisions': Health minister defends out-of-country drug funding rules as cancer patients face limited options — NWONewsWatch (The Trillium)
- Hansard, Legislative Assembly of Ontario, Oct. 27, 2026 (Question Period: Health care funding)
- Hansard, Legislative Assembly of Ontario, Oct. 28, 2026 (Question Period: Health care funding)
- Legislative Assembly of Ontario: Hansard, Nov. 4, 2026
- The Trillium: Ontario refused cancer patient's U.S. treatment and never told her its own health agency recommended funding it, FOI reveals
- CTV News Toronto: 'The clock is ticking:' Ontario woman says she was denied coverage for drug to treat her rare cancer
- Legislative Assembly of Ontario: Hansard, Nov. 5, 2026

